Search Result "CYP2D6 interactions"
Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction
Journal: Current Computer-Aided Drug Design
Volume: 13 Issue: 1 Year: 2017 Page: 39-47
Author(s): Olujide O. Olubiyi, Maryam O. Olagunju, Abiola O. Obisesan
An Evaluation of Ondansetron Binding Interactions with Human Cytochrome P450 Enzymes CYP3A4 and CYP2D6
Journal: Drug Metabolism Letters
Volume: 4 Issue: 1 Year: 2010 Page: 25-30
Author(s): David F.V. Lewis, Yuko Ito, Peter J. Eddershaw, Maurice Dickinsd, Peter S. Goldfarb
Clinical Implications of CYP2D6 Genetic Polymorphism During Treatment with Antipsychotic Drugs
Journal: Current Drug Targets
Volume: 7 Issue: 1 Year: 2006 Page: 1671-1680
Author(s): P. Dorado, R. Berecz, E. M. Penas-Lledo, M. C. Caceres, A. Llerena
Potential Minor Haplotypes of CYP2D6 in the Japanese Population
Journal: Drug Metabolism Letters
Volume: 11 Issue: 1 Year: 2017 Page: 53-59
Author(s): Masatoshi Masuda,Tsutomu Fujiwara,Masayuki Matsunaga,Takehisa Matsumaru
Difference in Desipramine Metabolic Profile Between Wild-Type and CYP2D6-Humanized Mice
Journal: Drug Metabolism Letters
Volume: 3 Issue: 4 Year: 2009 Page: 234-241
Author(s): Hong-Wu Shen, Ai-Ming Yu
Development and Validation of HPLC Methods for the Determination of CYP2D6 and CYP3A4 Activities
Journal: Current Pharmaceutical Analysis
Volume: 8 Issue: 3 Year: 2012 Page: 219-224
Author(s): Yan Pan,Joon Wah Mak,Chin Eng Ong
CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia
Journal: Current Cancer Drug Targets
Volume: 20 Issue: 9 Year: 2020 Page: 675-680
Author(s): Hadeil M.E. Idris,Hiba B. Khalil,Jeremy Mills,Abozer Y. Elderdery
Molecular Analysis and Modeling of Inactivation of Human CYP2D6 by Four Mechanism Based Inactivators
Journal: Drug Metabolism Letters
Volume: 6 Issue: 1 Year: 2012 Page: 7-14
Author(s): Mara Livezey, Leslie D. Nagy, Laura E. Diffenderfer, Evan J. Arthur, David J. Hsi, Jeffrey M. Holton, Laura Lowe Furge
How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments
Journal: Current Drug Metabolism
Volume: 11 Issue: 3 Year: 2010 Page: 276-282
Author(s): Manuela De Gregori, Massimo Allegri, Simona De Gregori, Giulia Garbin, Carmine Tinelli, Mario Regazzi, Stefano Govoni, Guglielmina Nadia Ranzani
Potential Polymorphic CYP1A2 and CYP2D6-mediated PharmacokineticInteractions between Risperidone or Olanzapine and Selected DrugsIntended to Treat COVID-19
Journal: Drug Metabolism and Bioanalysis Letters
Volume: 16 Issue: 1 Year: 2023 Page: 6-13
Author(s): Angel Tito Alvarado Yarasca